Management of Isotretinoin-Induced Blistering

Introduction to Isotretinoin-Induced Blistering

The British Journal of Dermatology recommends suspending isotretinoin immediately and consulting a dermatologist urgently, as blisters represent a severe adverse reaction that requires treatment interruption 1
The British Journal of Dermatology suggests contacting a dermatologist on the same day for urgent evaluation, as blistering lesions during isotretinoin treatment can represent significant cutaneous toxicity 1
According to the British Journal of Dermatology, patients should not restart the medication on their own, even if the blisters improve, to avoid further complications 1

The British Journal of Dermatology indicates that skin fragility and blister formation suggest the dose may be excessive for the patient's skin type, especially if they have acne with a marked erythematous or inflammatory component 1
Patients with marked erythroderma or very sensitive skin may develop cutaneous irritation, fragility, or blisters with isotretinoin, requiring very low doses (less than 25-30 mg/day in adults) or complete suspension, as recommended by the British Journal of Dermatology 1
The Annals of Oncology suggests that a dermatologist should examine the blisters to determine if they are secondary to isotretinoin toxicity, superimposed infection, or a severe allergic reaction 2
The Annals of Oncology recommends obtaining bacterial, viral, or fungal cultures if there is suspicion of superimposed infection 2
The British Journal of Dermatology advises evaluating the extent and severity of the blistering lesions to determine if treatment can be restarted at a much lower dose or if it should be permanently discontinued 1

The British Journal of Dermatology suggests that restarting isotretinoin at an extremely low dose (10 mg/day or less in adults, or even every third day) may be considered only if the blisters were mild and have completely resolved 1
The British Journal of Dermatology recommends close monitoring every 1-2 weeks if treatment is restarted 1
The Journal of the American Academy of Dermatology indicates that in cases of fulminant acne or isotretinoin-induced eruptions, prednisone 0.5-1 mg/kg/day with gradual tapering over several months may be required 3

The Annals of Oncology advises avoiding manipulation or breaking of blisters to prevent secondary infection 2
The Annals of Oncology recommends keeping the area clean and dry 4
The Annals of Oncology suggests using non-alcoholic and non-irritating moisturizing creams 4, 2
The Annals of Oncology advises avoiding excessive sun exposure and using sunscreen with SPF 15 or higher 4
The Annals of Oncology recommends avoiding hot water, frequent washing, and skin irritants 4, 2

Avoid frequent washing with hot water, limit to twice daily with lukewarm water, and completely avoid skin irritants including over-the-counter anti-acne medications, alcohol-based products, solvents, and disinfectants, as recommended by the American Cancer Society, based on evidence from Annals of Oncology 5
Do not use products containing salicylic acid, benzoyl peroxide, or other active acne ingredients while on isotretinoin, as these will cause excessive irritation, according to the American Academy of Dermatology 6
Wash face only twice daily with gentle, non-irritating cleanser, use lukewarm water, and pat dry gently rather than rubbing, as suggested by the American Cancer Society, based on evidence from Annals of Oncology 5

Apply alcohol-free, non-comedogenic moisturizing creams or ointments twice daily immediately after cleansing, as recommended by the American Cancer Society, based on evidence from Annals of Oncology 5
Moisturizers with 5%-10% urea content are particularly beneficial for managing the xerosis caused by isotretinoin, according to the British Association of Dermatologists, based on evidence from British Journal of Dermatology 7 and Annals of Oncology 5
Use broad-spectrum sunscreen (UVA/UVB) with SPF 15 or higher daily on all exposed skin, and reapply every 2 hours when outdoors, as recommended by the American Cancer Society, based on evidence from Annals of Oncology 5